题名 |
Hydromorphone:臺灣新上市鴉片類止痛劑 |
并列篇名 |
Hydromorphone: A New Opioid Marketed in Taiwan |
DOI |
10.3966/168395442014061401003 |
作者 |
姜紹青(Shao-Chin Chiang) |
关键词 |
鴉片受器 ; 鴉片類藥品轉換 ; 滲透壓控制釋放口服送藥系統 ; semisynthetic compound ; agonis ; osmotic-controlled release oral delivery system (OROS) |
期刊名称 |
腫瘤護理雜誌 |
卷期/出版年月 |
14卷1期(2014 / 06 / 01) |
页次 |
25 - 33 |
内容语文 |
繁體中文 |
中文摘要 |
衛生福利部食品藥物管理局管制藥品管理組終於在醫療人員長期等待下,於今(2014)年7月開始在台灣上市一個新的鴉片類成分hydromorphone。這個新的成分將提供台灣的慢性疼痛病人另一個選擇。本文介紹這個新的成份也介紹這個新上市的產品,協助醫療人員進一步認識這個藥品,也可以正確地使用這個新產品。 |
英文摘要 |
Hydromorphone, a semisynthetic compound, is a more potent opioid than morphine. Like morphine, it is mainly a μ agonist with little effect on δ receptor. It is metabolized by liver via first-pass effect. The action duration is approximately 4 hours, like morphine. However, the design of extended release could prolong the action duration to 12 hours and even to 24 hours. The metabolites of hydromorphone, unlike morphine, are mainly hydromorphone-3-glucuronide and do not include carbon-6 glucuronidation. Currently, the product approved by Taiwan Food and Drug Administration is a product of extended release, which is an osmotic-controlled release oral delivery system (OROS). This product should be started after using an immediate-release opioid and reach a stable dose. This article also provides detailed information on the clinical trials and its precaution in using Hydromorphone. |
主题分类 |
醫藥衛生 >
預防保健與衛生學 醫藥衛生 > 內科 醫藥衛生 > 社會醫學 |